Abu Dhabi has successfully wrapped up a groundbreaking clinical trial, testing a stem cell therapy for knee osteoarthritis. Conducted by the Department of Health – Abu Dhabi (DoH) in partnership with Cellcolabs and Burjeel Holdings, the trial marks a significant step forward in regenerative medicine.

The treatment, called StromaForte and developed by Swedish biotech firm Cellcolabs, uses Mesenchymal Stem Cells (MSCs) to target pain and inflammation in knee joints. These cells, found naturally in the body, help repair damaged tissue and encourage natural healing processes.

During the trial, patients received single-dose injections of MSCs, derived from healthy donors aged 18 to 30, directly into their knees. Conducted at Burjeel Medical City and Burjeel Hospital, the study ran from November 2023 to October 2024. Results from this Phase I/II trial showed promising outcomes; pain levels dropped significantly, with patients reporting improved mobility and quality of life. Importantly, no serious side effects were noted.

Dr. Asma Al Mannaei, Executive Director at DoH Abu Dhabi, emphasized the trial’s importance, stating, as reported by WAM, that it highlights Abu Dhabi’s role as a global hub for health innovation. She added that the emirate is committed to advancing cell and gene therapies while maintaining strict safety standards.

The therapy’s impact is still being studied, with MRI scans providing further insights. Findings will be unveiled during Abu Dhabi Global Health Week in April 2025.

Cellcolabs’ CEO, Peter Ekstedt, noted that this trial is a milestone for both the UAE and regenerative medicine, adding that the collaboration between DoH, Cellcolabs, and Burjeel Medical City is paving the way for non-surgical solutions to osteoarthritis.

Burjeel Holdings’ Group Chief Research Officer, Prof. Khaled Musallam, praised the results, saying the trial showcases Abu Dhabi’s growing biotech sector and the potential for stem cell treatments to transform patient care.

With this promising step forward, Abu Dhabi solidifies its reputation as a leader in cutting-edge medical research and innovation.